EUCTR2010-018774-21-DE进行中（未招募）不适用
OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Outpatients aged 40-70 years
- •? Male and female gender (females of childbearing potential must be using adequate contraceptive precautions such as implants, injectables, combined oral contraceptives, intrauterine devices, sexual abstinence or vasectomised partner)
- •? Females of childbearing potential or within two years from the menopause must have a negative urine pregnancy test
- •? Patients with essential hypertension never treated or taking one or two antihypertensive
- •medications (excluding combinations including test drugs), but not-normalised (mean sitting
- •OSBP between 140 and 179 mmHg and mean sitting ODBP between 90 and 109 mmHg)
- •? Type II diabetes mellitus controlled by diet or oral hypoglycaemic drug treatment (HbA1c
- •=7.5% confirmed at V2
- •? Able and willing to sign informed consent and to comply with study procedures
- •? Written informed consent prior to enrolment into the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Malignant or secondary hypertension
- •? Isolated systolic hypertension (sitting OSBP ?140 mmHg and ODBP <90 mmHg)
- •? Orthostatic hypotension (difference between mean sitting and standing SBP ? 20 mmHg)
- •? Myocardial infarction or unstable angina at the time of enrolment
- •? Cerebrovascular events in the previous 3 months
- •? Heart failure requiring medical treatment
- •? Body mass index ?35 kg/m2
- •? Any clinically relevant haematological or biochemical abnormality on routine screening, according to Investigator?s judgment
- •? Liver pathology (AST or ALT >3 times greater than normal upper limit or total serum bilirubin >1.5 times greater than normal upper limit)*
- •? Renal insufficiency (creatininemia >176,8 µmol/L or 2 mg/dL)
- •? Severe concurrent pathology, including terminal illness (cancer, AIDS, etc.)
- •? Insulin treatment
- •? Dementia, psychosis, alcoholism (>350 g ethanol/week) or chronic abuse of medicines, drugs or psychoactive substances
- •? Cardiogenic or septic shock
- •? Haemodynamically significant valvulopathy
- •? Hereditary/idiopathic angioedema
- •? History of angioedema associated with previous ACE-inhibitor therapy
- •? Bilateral renal arterial stenosis, or unilateral for patients with a single kidney
- •? Hypokalemia (<3.5 mEq/L) or hyperkalemia (>5.0 mEq/L) shown in at least two haematological examinations (if the patient presents at baseline with hypo or hyperkalemia, this value must be re-tested during run-in period). Before inclusion in the study the patient must have a normal potassium value.*
- •? Females who are pregnant or lactating
- •? Hypersensitivity or contraindications to treatment with AT1-antagonists, ACE-inhibitors or calcium-antagonists
- •? History of undesired side effects with AT1-antagonists, ACE-inhibitors or calcium-antagonists
- •? Introduction of concurrent therapies among those not permitted and which cannot be suspended without harm to the patient
- •? Concurrent or recent (?1 month) participation in other clinical trials
- •? Conditions which in the Investigator?s opinion may interfere with the study?s execution or due to which the patient should not participate for safety reasons
- •? Risk of low patient cooperation
- •? Inability or unwillingness to issue the informed consent
研究者
相似试验
进行中（未招募）
不适用
OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)MedDRA version: 12.1Level: LLTClassification code 10015488Term: Essential hypertensionHypertensionEUCTR2010-018774-21-GRMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA240
进行中（未招募）
1 期
OLMESARTAN +AMLOIPINE TREATMENT IN DIABETIC PATIENTS: EVALUATING BLOOD PRESSURE CONTROL AFTER 48 HOURS FROM THE LAST ADMINISTRATION (MISSED DOSE)MedDRA version: 12.1 Level: LLT Classification code 10015488 Term: Essential hypertensionHypertensionEUCTR2010-018774-21-FRMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG SA260
进行中（未招募）
不适用
Olmesartan + Amlodipine treatment in diabetic patients: evaluating blood pressure control after 48 hours from last administration (missed dose)HypertensionEUCTR2010-018774-21-ITMENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.240
进行中（未招募）
不适用
Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study - ROADMAPDiabetes mellitus type II / Prevention of microalbuminuriaClassification code 10029402EUCTR2004-000506-52-CZSankyo Pharma GmbH4,400
进行中（未招募）
不适用
Randomised Olmesartan and Diabetes Microalbuminuria Prevention Study - RoadmapIDDM (no insulin dependent diabetes mellitus)Classification code 10029402EUCTR2004-000506-52-LVSankyo Pharma GmbH4,400